Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant therapeutic hepatitis B lentiviral vector
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
The recombinant therapeutic hepatitis B lentiviral vector is a non-integrative lentiviral vector designed as a therapeutic vaccine for chronic hepatitis B virus (HBV) infection. It functions by delivering genetic material encoding HBV antigens, such as core, preS1, or large HBsAg, into host cells. This process aims to stimulate the host's immune system, specifically T-cells, to mount a robust and specific immune response against HBV-infected hepatocytes and viral antigens. The ultimate goal is to deplete HBV-positive hepatocytes and reduce or eliminate serum Hepatitis B surface Antigen (HBsAg), leading to a potential functional cure for chronic hepatitis B. This therapeutic approach has been developed through a collaborative effort involving Fudan University, Changzhi People's Hospital, Université de Paris Cité, Jinwei Biotechnology, Henzhun Biotechnology, and TheraVectys S.A.
- Other names
- lentiviral-vectored therapeutic vaccine for chronic hepatitis B重组治疗用乙型肝炎慢病毒载体注射液
02
Targets
LHBs (Hepatitis B virus large surface protein)
Beyond the preview
Go deeper on recombinant therapeutic hepatitis B lentiviral vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant therapeutic hepatitis B lentiviral vector.